Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 26

1.

Human biodistribution and dosimetry of [18F]nifene, an α4β2* nicotinic acetylcholine receptor PET tracer.

Betthauser TJ, Hillmer AT, Lao PJ, Ehlerding E, Mukherjee J, Stone CK, Christian BT.

Nucl Med Biol. 2017 Dec;55:7-11. doi: 10.1016/j.nucmedbio.2017.08.001. Epub 2017 Aug 17.

PMID:
28963927
2.

Radiation dosimetry of the α4β2 nicotinic receptor ligand (+)-[18F]flubatine, comparing preclinical PET/MRI and PET/CT to first-in-human PET/CT results.

Kranz M, Sattler B, Tiepolt S, Wilke S, Deuther-Conrad W, Donat CK, Fischer S, Patt M, Schildan A, Patt J, Smits R, Hoepping A, Steinbach J, Sabri O, Brust P.

EJNMMI Phys. 2016 Dec;3(1):25. Epub 2016 Oct 21.

3.

Imaging of cerebral α4β2* nicotinic acetylcholine receptors with (-)-[(18)F]Flubatine PET: Implementation of bolus plus constant infusion and sensitivity to acetylcholine in human brain.

Hillmer AT, Esterlis I, Gallezot JD, Bois F, Zheng MQ, Nabulsi N, Lin SF, Papke RL, Huang Y, Sabri O, Carson RE, Cosgrove KP.

Neuroimage. 2016 Nov 1;141:71-80. doi: 10.1016/j.neuroimage.2016.07.026. Epub 2016 Jul 15.

4.

Decreased Nicotinic Receptor Availability in Smokers with Slow Rates of Nicotine Metabolism.

Dubroff JG, Doot RK, Falcone M, Schnoll RA, Ray R, Tyndale RF, Brody AL, Hou C, Schmitz A, Lerman C.

J Nucl Med. 2015 Nov;56(11):1724-9. doi: 10.2967/jnumed.115.155002. Epub 2015 Aug 13.

5.

Evaluation of [(18)F]-(-)-norchlorofluorohomoepibatidine ([(18)F]-(-)-NCFHEB) as a PET radioligand to image the nicotinic acetylcholine receptors in non-human primates.

Bois F, Gallezot JD, Zheng MQ, Lin SF, Esterlis I, Cosgrove KP, Carson RE, Huang Y.

Nucl Med Biol. 2015 Jun;42(6):570-7. doi: 10.1016/j.nucmedbio.2014.08.003. Epub 2014 Aug 8.

6.

Involvement of neuronal β2 subunit-containing nicotinic acetylcholine receptors in nicotine reward and withdrawal: implications for pharmacotherapies.

Simmons SJ, Gould TJ.

J Clin Pharm Ther. 2014 Oct;39(5):457-67. doi: 10.1111/jcpt.12171. Epub 2014 May 14. Review.

7.

Radiosyntheses using fluorine-18: the art and science of late stage fluorination.

Cole EL, Stewart MN, Littich R, Hoareau R, Scott PJ.

Curr Top Med Chem. 2014;14(7):875-900. Review.

8.
9.

Thalamic cholinergic innervation and postural sensory integration function in Parkinson's disease.

Müller ML, Albin RL, Kotagal V, Koeppe RA, Scott PJ, Frey KA, Bohnen NI.

Brain. 2013 Nov;136(Pt 11):3282-9. doi: 10.1093/brain/awt247. Epub 2013 Sep 20.

10.

Measuring α4β2* nicotinic acetylcholine receptor density in vivo with [(18)F]nifene PET in the nonhuman primate.

Hillmer AT, Wooten DW, Slesarev MS, Ahlers EO, Barnhart TE, Schneider ML, Mukherjee J, Christian BT.

J Cereb Blood Flow Metab. 2013 Nov;33(11):1806-14. doi: 10.1038/jcbfm.2013.136. Epub 2013 Aug 14.

11.

Nicotinic α4β2 receptor imaging agents. Part IV. Synthesis and biological evaluation of 3-(2-(S)-3,4-dehydropyrrolinyl methoxy)-5-(3'-¹⁸F-fluoropropyl)pyridine (¹⁸F-Nifrolene) using PET.

Pichika R, Kuruvilla SA, Patel N, Vu K, Sinha S, Easwaramoorthy B, Narayanan TK, Shi B, Christian B, Mukherjee J.

Nucl Med Biol. 2013 Jan;40(1):117-25. doi: 10.1016/j.nucmedbio.2012.09.009. Epub 2012 Nov 7.

12.

PET imaging of α4β2* nicotinic acetylcholine receptors: quantitative analysis of 18F-nifene kinetics in the nonhuman primate.

Hillmer AT, Wooten DW, Slesarev MS, Ahlers EO, Barnhart TE, Murali D, Schneider ML, Mukherjee J, Christian BT.

J Nucl Med. 2012 Sep;53(9):1471-80. doi: 10.2967/jnumed.112.103846. Epub 2012 Jul 31.

13.
14.

Brain imaging of nicotinic receptors in Alzheimer's disease.

Wu J, Ishikawa M, Zhang J, Hashimoto K.

Int J Alzheimers Dis. 2010 Dec 28;2010:548913. doi: 10.4061/2010/548913.

15.

Direction and magnitude of nicotine effects on the fMRI BOLD response are related to nicotine effects on behavioral performance.

Warbrick T, Mobascher A, Brinkmeyer J, Musso F, Stoecker T, Shah NJ, Vossel S, Winterer G.

Psychopharmacology (Berl). 2011 May;215(2):333-44. doi: 10.1007/s00213-010-2145-8. Epub 2011 Jan 18.

16.

Clinical Perspective and Recent Development of PET Radioligands for Imaging Cerebral Nicotinic Acetylcholine Receptors.

Horti AG, Wong DF.

PET Clin. 2009 Jan 1;4(1):89-100. doi: 10.1016/j.cpet.2009.04.014. No abstract available.

17.

Synthesis and biological evaluation of novel carbon-11 labeled pyridyl ethers: candidate ligands for in vivo imaging of alpha4beta2 nicotinic acetylcholine receptors (alpha4beta2-nAChRs) in the brain with positron emission tomography.

Gao Y, Ravert HT, Kuwabara H, Xiao Y, Endres CJ, Hilton J, Holt DP, Kumar A, Alexander M, Wong DF, Dannals RF, Horti AG.

Bioorg Med Chem. 2009 Jul 1;17(13):4367-77. doi: 10.1016/j.bmc.2009.05.021. Epub 2009 May 15.

18.

Single photon emission computed tomography experience with (S)-5-[(123)I]iodo-3-(2-azetidinylmethoxy)pyridine in the living human brain of smokers and nonsmokers.

Brasić JR, Zhou Y, Musachio JL, Hilton J, Fan H, Crabb A, Endres CJ, Reinhardt MJ, Dogan AS, Alexander M, Rousset O, Maris MA, Galecki J, Nandi A, Wong DF.

Synapse. 2009 Apr;63(4):339-58. doi: 10.1002/syn.20611.

19.

[11C]CHIBA-1001 as a novel PET ligand for alpha7 nicotinic receptors in the brain: a PET study in conscious monkeys.

Hashimoto K, Nishiyama S, Ohba H, Matsuo M, Kobashi T, Takahagi M, Iyo M, Kitashoji T, Tsukada H.

PLoS One. 2008 Sep 18;3(9):e3231. doi: 10.1371/journal.pone.0003231.

20.

Greater nicotinic acetylcholine receptor density in smokers than in nonsmokers: a PET study with 2-18F-FA-85380.

Mukhin AG, Kimes AS, Chefer SI, Matochik JA, Contoreggi CS, Horti AG, Vaupel DB, Pavlova O, Stein EA.

J Nucl Med. 2008 Oct;49(10):1628-35. doi: 10.2967/jnumed.108.050716. Epub 2008 Sep 15.

Supplemental Content

Support Center